[{"id":"eb2c9586-b73c-4df1-a8ec-071b3eb87105","acronym":"","url":"https://clinicaltrials.gov/study/NCT04872413","created_at":"2021-05-04T11:52:42.604Z","updated_at":"2025-02-25T14:02:19.374Z","phase":"","brief_title":"Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial","source_id_and_acronym":"NCT04872413","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD20 • CCND1","pipe":"","alterations":" ","tags":["CD20 • CCND1"],"overall_status":"Suspended","enrollment":" Enrollment 20","initiation":"Initiation: 03/04/2021","start_date":" 03/04/2021","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2025-02-19"},{"id":"8058c94b-0d21-42b2-b6cf-b07e05abfcb1","acronym":"PRO00037171","url":"https://clinicaltrials.gov/study/NCT04186520","created_at":"2021-07-05T17:26:53.958Z","updated_at":"2025-02-25T14:15:30.805Z","phase":"Phase 1/2","brief_title":"CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies","source_id_and_acronym":"NCT04186520 - PRO00037171","lead_sponsor":"Medical College of Wisconsin","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CAR-20/19-T Cells"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/18/2020","start_date":" 05/18/2020","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-02-18"},{"id":"113cfda4-7d09-419b-a619-1fc822fa3cf6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03088878","created_at":"2021-01-18T15:13:07.925Z","updated_at":"2025-02-25T15:17:25.790Z","phase":"Phase 1/2","brief_title":"A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies","source_id_and_acronym":"NCT03088878","lead_sponsor":"Oncternal Therapeutics, Inc","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • zilovertamab (UC-961)"],"overall_status":"Completed","enrollment":" Enrollment 95","initiation":"Initiation: 01/03/2018","start_date":" 01/03/2018","primary_txt":" Primary completion: 09/25/2024","primary_completion_date":" 09/25/2024","study_txt":" Completion: 09/25/2024","study_completion_date":" 09/25/2024","last_update_posted":"2025-02-12"},{"id":"82e136f4-d38a-459f-8a3f-411cfccafc31","acronym":"","url":"https://clinicaltrials.gov/study/NCT05495464","created_at":"2022-08-10T12:55:30.197Z","updated_at":"2025-02-25T15:00:33.482Z","phase":"Phase 1","brief_title":"A Pilot \"Window-3\" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients with Previously Untreated High-risk Mantle Cell Lymphoma","source_id_and_acronym":"NCT05495464","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • FAT1 • POT1 • NSD2 • UBR5","pipe":" | ","alterations":" CD20 positive • Chr t(11;14)","tags":["TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • FAT1 • POT1 • NSD2 • UBR5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • Calquence (acalabrutinib) • fludarabine IV • Tecartus (brexucabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/18/2022","start_date":" 11/18/2022","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-12"},{"id":"825e707d-d24d-4a05-b786-1228f5cc02ad","acronym":"Window-2","url":"https://clinicaltrials.gov/study/NCT03710772","created_at":"2021-01-18T18:11:30.804Z","updated_at":"2025-02-25T15:34:12.058Z","phase":"Phase 2","brief_title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT03710772 - Window-2","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CD20 • NSD2","pipe":" | ","alterations":" TP53 mutation • CD20 positive","tags":["TP53 • CD20 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 05/22/2025","primary_completion_date":" 05/22/2025","study_txt":" Completion: 05/22/2025","study_completion_date":" 05/22/2025","last_update_posted":"2025-02-11"},{"id":"33ca6a18-d45b-42c8-9bb0-e546b4b79d4d","acronym":"GLOBRYTE","url":"https://clinicaltrials.gov/study/NCT06084936","created_at":"2023-10-16T15:12:59.101Z","updated_at":"2025-02-25T16:33:44.879Z","phase":"Phase 3","brief_title":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT06084936 - GLOBRYTE","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CCND1","pipe":" | ","alterations":" Chr t(11;14)","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • Gazyva (obinutuzumab) • bendamustine • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)"],"overall_status":"Recruiting","enrollment":" Enrollment 182","initiation":"Initiation: 10/22/2023","start_date":" 10/22/2023","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-07"},{"id":"90b17306-08d8-42c8-b26e-2dd99b9fda58","acronym":"","url":"https://clinicaltrials.gov/study/NCT01880567","created_at":"2021-01-18T08:25:52.475Z","updated_at":"2025-02-25T16:36:16.363Z","phase":"Phase 2","brief_title":"Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT01880567","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD20 • CCND1 • CCND3","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CCND1 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 07/15/2013","start_date":" 07/15/2013","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2025-02-07"},{"id":"7fd7343b-e00a-415f-aa0d-62ed50ea285e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02051257","created_at":"2021-01-18T09:25:59.407Z","updated_at":"2025-02-25T16:43:46.952Z","phase":"Phase 1","brief_title":"Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT02051257","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD28","pipe":" | ","alterations":" CD28 expression","tags":["CD28"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD28 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 CAR T cells"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 06/19/2014","start_date":" 06/19/2014","primary_txt":" Primary completion: 03/24/2025","primary_completion_date":" 03/24/2025","study_txt":" Completion: 03/24/2025","study_completion_date":" 03/24/2025","last_update_posted":"2025-02-06"},{"id":"7f3a4417-d9e1-41f2-85e6-183300a2b151","acronym":"NCI-2017-01311","url":"https://clinicaltrials.gov/study/NCT03246906","created_at":"2021-01-18T16:02:34.370Z","updated_at":"2025-02-25T16:44:11.978Z","phase":"Phase 2","brief_title":"Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation","source_id_and_acronym":"NCT03246906 - NCI-2017-01311","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • cyclosporin A microemulsion • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 09/11/2017","start_date":" 09/11/2017","primary_txt":" Primary completion: 05/03/2025","primary_completion_date":" 05/03/2025","study_txt":" Completion: 05/03/2025","study_completion_date":" 05/03/2025","last_update_posted":"2025-02-05"},{"id":"0d9ce0fd-f1c5-49a0-8195-840b50eca958","acronym":"MT2015-29","url":"https://clinicaltrials.gov/study/NCT03314974","created_at":"2021-01-18T16:22:16.872Z","updated_at":"2025-02-25T16:52:01.168Z","phase":"Phase 2","brief_title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","source_id_and_acronym":"NCT03314974 - MT2015-29","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement","tags":["NPM1 • KMT2A • IKZF1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2026","study_completion_date":" 06/10/2026","last_update_posted":"2025-02-04"},{"id":"37db9b88-cfea-407b-b290-ec67bb7844d2","acronym":"EPCORE NHL-5","url":"https://clinicaltrials.gov/study/NCT05283720","created_at":"2022-03-17T12:53:27.504Z","updated_at":"2025-02-25T16:54:10.677Z","phase":"Phase 2","brief_title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05283720 - EPCORE NHL-5","lead_sponsor":"Genmab","biomarkers":" BCL2 • CD20 • CCND1 • BCL6","pipe":" | ","alterations":" Chr t(11;14)","tags":["BCL2 • CD20 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • prednisone • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp) • Polivy (polatuzumab vedotin-piiq) • golcadomide (CC-99282)"],"overall_status":"Recruiting","enrollment":" Enrollment 622","initiation":"Initiation: 06/14/2022","start_date":" 06/14/2022","primary_txt":" Primary completion: 11/01/2032","primary_completion_date":" 11/01/2032","study_txt":" Completion: 11/01/2032","study_completion_date":" 11/01/2032","last_update_posted":"2025-02-04"},{"id":"93cce817-ed7e-442e-95cd-47f76d702a46","acronym":"","url":"https://clinicaltrials.gov/study/NCT02159755","created_at":"2021-01-18T10:03:07.008Z","updated_at":"2025-02-25T16:51:23.872Z","phase":"Phase 1","brief_title":"Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma","source_id_and_acronym":"NCT02159755","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CCND1 • CD5","pipe":" | ","alterations":" Chr t(11;14)","tags":["CCND1 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 05/20/2014","start_date":" 05/20/2014","primary_txt":" Primary completion: 06/25/2018","primary_completion_date":" 06/25/2018","study_txt":" Completion: 01/20/2026","study_completion_date":" 01/20/2026","last_update_posted":"2025-02-04"},{"id":"963274c2-ef1a-43d9-bccd-99053c776187","acronym":"","url":"https://clinicaltrials.gov/study/NCT04599634","created_at":"2023-06-02T17:05:43.963Z","updated_at":"2025-02-25T16:53:20.802Z","phase":"Phase 1","brief_title":"Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies","source_id_and_acronym":"NCT04599634","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • BCL2","pipe":" | ","alterations":" TP53 mutation • CD20 positive","tags":["TP53 • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • magrolimab (ONO-7913) • methylprednisolone acetate • methylprednisolone sodium succinate"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 12/16/2021","start_date":" 12/16/2021","primary_txt":" Primary completion: 03/29/2024","primary_completion_date":" 03/29/2024","study_txt":" Completion: 06/20/2024","study_completion_date":" 06/20/2024","last_update_posted":"2025-02-04"},{"id":"6fb8e6bc-6843-426e-b257-f87a181c8030","acronym":"","url":"https://clinicaltrials.gov/study/NCT04855695","created_at":"2021-04-22T20:53:44.057Z","updated_at":"2025-02-25T14:59:49.341Z","phase":"Phase 1/2","brief_title":"Avo In R/R And Previously Untreated MCL","source_id_and_acronym":"NCT04855695","lead_sponsor":"Austin I Kim","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 07/02/2021","start_date":" 07/02/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-01-29"},{"id":"b3cbc60c-b805-4974-b2a9-560e9eb38edd","acronym":"NCI-2018-00315","url":"https://clinicaltrials.gov/study/NCT03479268","created_at":"2021-01-18T17:08:37.744Z","updated_at":"2025-02-25T17:35:59.375Z","phase":"Phase 1","brief_title":"Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03479268 - NCI-2018-00315","lead_sponsor":"City of Hope Medical Center","biomarkers":" CCND1 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CCND1 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/22/2018","start_date":" 03/22/2018","primary_txt":" Primary completion: 06/22/2025","primary_completion_date":" 06/22/2025","study_txt":" Completion: 06/22/2025","study_completion_date":" 06/22/2025","last_update_posted":"2025-01-29"},{"id":"41b81518-c725-4e13-b21e-3394ebef8619","acronym":"ACALLO","url":"https://clinicaltrials.gov/study/NCT04716075","created_at":"2021-03-14T06:44:32.030Z","updated_at":"2025-02-25T14:59:39.243Z","phase":"Phase 2","brief_title":"Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)","source_id_and_acronym":"NCT04716075 - ACALLO","lead_sponsor":"Polish Lymphoma Research Group","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 08/19/2019","start_date":" 08/19/2019","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 07/30/2024","study_completion_date":" 07/30/2024","last_update_posted":"2025-01-16"},{"id":"432afcf2-c0ff-473d-b0bb-573d93966393","acronym":"","url":"https://clinicaltrials.gov/study/NCT06544265","created_at":"2025-02-26T10:28:02.721Z","updated_at":"2025-02-26T10:28:02.721Z","phase":"Phase 1","brief_title":"SynKIR-310 for Relapsed/Refractory B-NHL","source_id_and_acronym":"NCT06544265","lead_sponsor":"Verismo Therapeutics","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/01/2024","start_date":" 11/01/2024","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-11-22"},{"id":"447ed126-6f5f-4987-b043-27e335f9b442","acronym":"C1763102","url":"https://clinicaltrials.gov/study/NCT05602363","created_at":"2024-01-29T15:19:20.293Z","updated_at":"2025-02-25T14:09:14.782Z","phase":"Phase 1","brief_title":"AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05602363 - C1763102","lead_sponsor":"Carna Biosciences, Inc.","biomarkers":" PLCG2","pipe":" | ","alterations":" PLCG2 mutation","tags":["PLCG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PLCG2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docirbrutinib (AS-1763)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-11-01"},{"id":"ade707b7-5e5b-4f00-a824-2c91c94d8afe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04578600","created_at":"2021-01-18T21:51:14.278Z","updated_at":"2025-02-25T14:29:38.782Z","phase":"Phase 1","brief_title":"CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma","source_id_and_acronym":"NCT04578600","lead_sponsor":"Joseph Tuscano","biomarkers":" CD20 • CD4","pipe":"","alterations":" ","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Gazyva (obinutuzumab) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 10/23/2020","start_date":" 10/23/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-09-19"},{"id":"259ce71b-5eef-4e8b-8117-2864d12c696a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01472562","created_at":"2021-01-18T06:08:26.175Z","updated_at":"2025-02-25T14:33:09.941Z","phase":"Phase 2","brief_title":"Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma","source_id_and_acronym":"NCT01472562","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CD20 • CCND1 • CD5 • CCND2 • MME • FCER2","pipe":" | ","alterations":" CCND1 overexpression • CCND2 overexpression","tags":["CD20 • CCND1 • CD5 • CCND2 • MME • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 overexpression • CCND2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 07/29/2011","start_date":" 07/29/2011","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 07/30/2023","study_completion_date":" 07/30/2023","last_update_posted":"2024-07-16"},{"id":"ccaab729-08e3-4b0f-ae17-a92ba3b288af","acronym":"","url":"https://clinicaltrials.gov/study/NCT02996773","created_at":"2021-01-18T14:44:29.668Z","updated_at":"2025-02-25T16:24:52.034Z","phase":"Phase 1","brief_title":"Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine","source_id_and_acronym":"NCT02996773","lead_sponsor":"University of Arizona","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/29/2016","start_date":" 11/29/2016","primary_txt":" Primary completion: 08/25/2025","primary_completion_date":" 08/25/2025","study_txt":" Completion: 08/25/2025","study_completion_date":" 08/25/2025","last_update_posted":"2024-07-11"},{"id":"59201174-86d0-4c21-b519-220173f5e9be","acronym":"ENABLE","url":"https://clinicaltrials.gov/study/NCT04049513","created_at":"2021-01-18T19:51:32.910Z","updated_at":"2024-07-02T16:34:26.420Z","phase":"Phase 1","brief_title":"ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)","source_id_and_acronym":"NCT04049513 - ENABLE","lead_sponsor":"Malaghan Institute of Medical Research","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • WZTL-002 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/11/2019","start_date":" 10/11/2019","primary_txt":" Primary completion: 06/12/2024","primary_completion_date":" 06/12/2024","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2024-06-13"},{"id":"731a7f94-ad73-4cc1-96c6-298d3b4cf270","acronym":"ZEBRA","url":"https://clinicaltrials.gov/study/NCT05635162","created_at":"2022-12-02T15:56:31.374Z","updated_at":"2024-07-02T16:34:26.777Z","phase":"Phase 2","brief_title":"Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma","source_id_and_acronym":"NCT05635162 - ZEBRA","lead_sponsor":"University College, London","biomarkers":" CCND1","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/17/2024","start_date":" 05/17/2024","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2024-06-12"},{"id":"d6470e31-1ef9-400d-8e4a-687104d9ddb3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03277729","created_at":"2021-01-18T16:11:11.702Z","updated_at":"2024-07-02T16:34:26.876Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas","source_id_and_acronym":"NCT03277729","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" BCL2","pipe":" | ","alterations":" CD20 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • MB-106"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 12/05/2017","start_date":" 12/05/2017","primary_txt":" Primary completion: 03/29/2024","primary_completion_date":" 03/29/2024","study_txt":" Completion: 11/16/2037","study_completion_date":" 11/16/2037","last_update_posted":"2024-06-12"}]